Sweden's Alligator Bioscience posts Q1 net profit, narrows operating loss

Alligator Bioscience AB

05/05/2026 07:08

Overview

Sweden biotech firm swung to Q1 net income from yr-ago loss, operating loss narrowed yr/yr

Company completed TO 14 warrant program, raising about 19 MSEK in gross proceeds

Lead drug mitazalimab advanced with new data presentations at major scientific meetings

Outlook

Company did not provide specific financial guidance for the current qtr or full yr

Result Drivers

MITAZALIMAB DATA - Co said new clinical and translational data presentations for mitazalimab strengthened the program's foundation

CAPITAL RAISE - Co completed TO 14 warrant program, raising about 19 MSEK in gross proceeds

Company press release: ID:nMFN6PFMhq

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Adjusted EPS
SEK 0
Q1 Net Income
SEK 1.40 mln
Q1 EBIT
-SEK 17.80 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)